Mizuho Downplays Merck (MRK) KEYTRUDA Competition in 1L NSCLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Merck (MRK) Tops Q3 EPS by 27c, Revenues Beat; Narrows & Raises FY19 EPS/Revenue Above Consensus
October 29, 2019 6:47 AM EDTMerck (NYSE: MRK) reported Q3 EPS of $1.51, $0.27 better than the analyst estimate of $1.24. Revenue for the quarter came in at $12.4 billion versus the consensus estimate of $11.63 billion.
Third-Quarter 2019 Worldwide Sales Were $12.4 Billion, an Increase of 15%; Sales Increased 16% Excluding Impact from Foreign Exchange; Growth Driven by Oncology and Human Health VaccinesKEYTRUDA Sales Grew 62% to $3.1 Billion;... MoreMerck (MRK) Trades Lower Following AstraZeneca (AZN) Imfinzi Results, Down 0.70%
October 28, 2019 11:39 AM EDTMerck (NYSE: MRK) Trades Lower Following AstraZeneca (NYSE: AZN) Imfinzi Results, Down 0.70%
... More